Press Releases

Thursday, September 19, 2013

In an effort to increase partnerships between women, veteran, minority and local businesses within Western New York, Catholic Health and Roswell Park Cancer Institute (RPCI) will be hosting a Vendor Fair on Wednesday, October 9 from 10 a.m. to 2 p.m. at the Millennium Hotel, located at 2040 Walden Avenue in Cheektowaga, N.Y.

Tuesday, September 17, 2013

Western New Yorkers are invited to attend a special screening of the film Decoding Annie Parker on Thursday, Sept. 26, with partial proceeds benefitting the Familial Ovarian Cancer Registry at Roswell Park Cancer Institute (RPCI). The film’s director, Steven Bernstein, is a Buffalo native who will return to Western New York for the film’s screening prior to its nationwide release. Funds from the event will also support BRCA Gene Awareness Inc.

Monday, September 16, 2013

Researchers at RPCI have uncovered a new pathway by which cancer cells, such as in breast cancer, stimulate the expansion of myeloid-derived suppressor cells (MDSCs), a blood cell population known to interfere with the body’s anti-tumor response. The findings shed new light on the pathological events that fuel tumor growth and could lead to the development of new therapies to hinder it.

Monday, September 16, 2013

Roswell Park Cancer Institute (RPCI) and the RPCI Hispanic Employee Network & Resource Group will celebrate Hispanic Heritage Month on Tuesday, Sept. 17, 2013 from 4:30 p.m. until 6 p.m.

Monday, September 9, 2013

WHAT: Prostate cancer has a disproportional impact on African-American men, who are 1.5 times more likely to develop prostate cancer and two to three times more likely to die of the disease than white men. Prostate cancer is also the most-diagnosed cancer in Hispanic men.

Thursday, August 29, 2013

Anthony L. Picone, MD, PhD, MBA, cardiothoracic surgeon in the Department of Thoracic Surgery, has been named medical director of Roswell Park Cancer Institute (RPCI). Dr. Picone has been employed at Roswell Park since April of 2009, and for the past six months has served as RPCI’s interim medical director.

Wednesday, August 14, 2013

How willing are smokers to try different tobacco products based on the price? Researchers at RPCI are asking that and other questions in a clinical study that examines the impact of price and other factors on the substitution of smokeless tobacco products for cigarettes. They're seeking 200 smokers who are willing to try new products and cut down on their smoking. The study will help to explain the motivation behind decisions about health and offer new insights on health-behavior change.

Thursday, August 1, 2013

In an effort to increase the number of minority investigators in clinical research, Eli Lilly and Company (NYSE: LLY) and The Center for Drug Development and Clinical Trials at Roswell Park Cancer Institute (RPCI) today announced a new collaborative training program specifically tailored to this growing group of investigators. This program is the first of its kind in the industry.

Friday, July 26, 2013

Roswell Park Cancer Institute (RPCI) is proud to announce that several faculty members have collectively received $4.9 million in grant funding from federal agencies and other sources. These grants help fund important research that aims to develop new ways to prevent and treat cancer and improve our patients’ quality of life.

Thursday, July 25, 2013

Researchers at Adaptimmune, RPCI and City of Hope announced the opening of a Phase I/IIa clinical trial in ovarian cancer at RPCI and City of Hope. The team will investigate the safety, bioactivity and effectiveness of treating patients with their own T cells after genetically engineering the cells to enhance their antitumor properties.

Wednesday, July 17, 2013

Longtime Orchard Park resident Elyse NeMoyer has joined the Roswell Park Cancer Institute (RPCI) Board of Directors. An occupational therapist, she was appointed to a three-year term on the board by state Sen. Andrea Stewart-Cousins, Democratic Conference Leader for the New York State Senate, based on the recommendation of state Sen. Timothy Kennedy.

Monday, July 8, 2013

Cleveland BioLabs, Inc. (NASDAQ:CBLI), Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures, and Roswell Park Cancer Institute (RPCI) today announced the publication of studies describing the Facilitates Chromatin Transcription (FACT) complex as an accelerator of tumor transformation and a potential marker and target for aggressive cancers in Cell Reports, a peer-reviewed journal.